Company
BeiGene
BeiGene has 25 drugs tracked on RxWires: 1 post-market, 4 in Phase 3, 8 in Phase 2, 3 in Phase 1/2, 9 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Zanubrutinib | Post-Market | Waldenström's Macroglobulinemia |
| Tislelizumab | Phase 3 | Esophageal Squamous Cell Carcinoma (ESCC) |
| Sitravatinib | Phase 3 | Hepatocellular Carcinoma |
| Pamiparib capsule | Phase 3 | Ovarian Cancer |
| BGB-3111 | Phase 3 | Waldenström's Macroglobulinemia |
| Brentuximab Vedotin in Combination with Tislelizumab | Phase 2 | NK/T Cell Lymphoma Nos |
| Bendamustine | Phase 2 | Mantle Cell Lymphoma |
| Lenvatinib | Phase 2 | Hepatocellular Carcinoma |
| BGB-A445 | Phase 2 | Non-small Cell Lung Cancer |
| BGB-A425 | Phase 2 | Head and Neck Squamous Cell Carcinoma |
| Ociperlimab | Phase 2 | Limited Stage Small Cell Lung Cancer |
| Tislelizumab combined with chemoradiotherapy | Phase 2 | ESCC |
| sonrotoclax | Phase 2 | Acute Myeloid Leukemia |
| BGB-A333 | Phase 1/2 | Advanced Solid Tumors |
| Alcestobart | Phase 1/2 | Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer |
| Zanidatamab | Phase 1/2 | Breast Cancer |
| ATRA | Phase 1 | Advanced Pancreatic Ductal Adenocarcinoma |
| BGB-DXP604 | Phase 1 | Healthy |
| BGB-15025 | Phase 1 | Advanced Solid Tumor |
| BGB-11417 | Phase 1 | Mature B-cell Malignancies |
| BG-68501 | Phase 1 | Breast Cancer |
| [14C]-BGB-16673 | Phase 1 | Healthy Volunteers |
| BGB DXP593 | Phase 1 | Covid19 |
| [14C]-BGB-11417 | Phase 1 | Healthy Volunteers |
| BGB-16673 | Phase 1 | Healthy Volunteers |
Latest
Follow BeiGene on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.